11116-32-8

Basic information

• Product Name: Bleomycin A5
• Synonyms: N1-(3-((4-Aminobutyl)amino)propyl)bleomycinamide;Pingyangmycin A5;Zhengguanmycin A5;Nsc350895;Bleomycinamide, N1-[3-[(4-aminobutyl)amino]propyl]-;bleomycetin;Bleomycin A5
• CAS NO: 11116-32-8
• Molecular Formula: C57H89N19O21S2
• Molecular Weight: 1440.57
• EINECS: 234-357-0
• Mol File: 11116-32-8.mol
• Article Data: 0

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.1028 (rough estimate)
• Refractive Index: 1.6700 (estimate)
• PKA: 10.84±0.46(Predicted)
• CAS DataBase Reference: Bleomycin A5(CAS DataBase Reference)
• NIST Chemistry Reference: Bleomycin A5(11116-32-8)
• EPA Substance Registry System: Bleomycin A5(11116-32-8)

Safety Data

• Hazardous Substances Data: 11116-32-8(Hazardous Substances Data)

Usage

Definition

ChEBI: A member of the class of bleomycins that is used in sclerotherapy for cervicofacial lymphatic malformations.

InChI:InChI=1/C61H89N19O21S2/c1-25-39(77-52(80-50(25)64)31(17-37(63)84)72-18-30(62)51(65)90)56(94)79-41(47(32-19-68-24-73-32)99-60-49(45(88)43(86)35(20-81)98-60)100-59-46(89)48(101-61(66)96)44(87)36(21-82)97-59)57(95)74-27(3)42(85)26(2)53(91)78-40(28(4)83)55(93)71-16-11-38-75-34(23-102-38)58-76-33(22-103-58)54(92)70-15-8-13-67-12-7-10-29-9-5-6-14-69-29/h5-6,9,14,19,22-24,26-28,30-31,35-36,40-49,59-60,67,72,81-83,85-89H,7-8,10-13,15-18,20-21,62H2,1-4H3,(H2,63,84)(H2,65,90)(H2,66,96)(H,68,73)(H,70,92)(H,71,93)(H,74,95)(H,78,91)(H,79,94)(H2,64,77,80)/t26-,27+,28+,30-,31-,35?,36?,40-,41-,42-,43?,44?,45?,46?,47-,48?,49?,59?,60?/m0/s1

Related news

A clinical study of ultrasound-guided intralesional injection of Bleomycin A5 (cas 11116-32-8) on venous malformation in cervical-facial region in China07/22/2019

ObjectivesTo evaluate the therapeutic outcome of ultrasound-guided intralesional injection of bleomycin A5 on treatment of venous malformation (VM) in cervical-facial region.detailed

Electrophoresis mobility shift assay and biosensor used in studying the interaction between Bleomycin A5 (cas 11116-32-8) and DNA07/20/2019

DNA is the potential target of numerous drugs utilized widely in clinical cancer therapy. Here we employed bleomycin A5, with its deactivated form as contrast, to investigate the interaction between small pharmaceutical and DNA. Electrophoresis mobility shift assay (EMSA) which is a common techn...detailed

Bleomycin A5 (cas 11116-32-8) plus dexamethasone for control of growth in infantile parotid hemangiomas07/21/2019

ObjectiveThe purpose of this study was to evaluate the efficacy of bleomycin A5 (pingyangmycin) plus dexamethasone for control of growth in infantile parotid hemangiomas.detailed

Bleomycin A5 (cas 11116-32-8) sclerotherapy for cervicofacial lymphatic malformations07/19/2019

ObjectivesThe purpose of this study was to document the results of bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations (LMs), and the clinical data of 65 patients between October 2004 and October 2007 were reviewed.detailed

How to use Bleomycin A5 (cas 11116-32-8) for infantile maxillofacial haemangiomas: Clinical evaluation of 82 consecutive cases07/18/2019

ObjectiveBleomycin A5 has been reported effective for infantile haemangioma (IH), but the usage and complications were described a little. We have used bleomycin A5 to treat maxillofacial IHs for 15 years. This paper describes the procedures to use bleomycin A5 and avoid its complications based ...detailed